endocrinologists expect to prescribe lower-cost biosimilar insulin analogues
within 12 months of launch.
The effects of anti-insulin antibodies and cross-reactivity with human recombinant insulin analogues
in the E170 insulin immunometric assay.
This study has the strengths of its large size, the good data it had on tumor type and covariants, its attempt to model the impact of a cumulative glargine dosage, and its ability to place the impact of glargine within the context of other insulin analogues
Concern has been expressed, moreover, about IGF-I receptor affinity and increased mitogenic potency of some of the insulin analogues
In this last issue of our Journal, you will find some interesting papers which are "Biphasic insulin analogues
in type 2 diabetes, expert panel recommendations," "Oxidative stress markers in metabolic syndrome," "Association of Sp1 Colagen Type lg1 gene polymorphisim with the bone mineral density," ganglioneuroma" and "Diabetic ketoasidosis.
expertise in the diabetes market and two basal insulin analogues
While still well short of this ideal, new therapeutic insulin analogues
are substantially closer to physiological profiles than older types of insulin still widely used in hospitals (3,7).
THE PHARMACEUTICAL Services of Cyprus have announced that they will not be ordering the discontinuation of the usage of the Insulin Glargine, following the conclusion of a European Medicines Agency investigation into possible links between the insulin analogues
Led by a collaborative team of researchers from the Institute for Quality and Efficiency in Health Care (IQWiG) and a research institute of the German Local Health Care Fund, the study analysed the data of almost 130,000 patients with diabetes in Germany who had been treated with either human insulin or the insulin analogues
lispro (trade name: Humalog), aspart (Novorapid) or glargine (Lantus) between January 2001 and June 2005.
Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that coverage of injectable type 2 diabetes therapies by public programs for pharmaceutical assistance in Brazil is limited to regular and NPH (neutral protamine Hagedorn) insulin and does not include any insulin analogues
or Glucagon-like peptide 1 (GLP-1) analogues.
Future outlook for insulin analogues
: Payers and physicians look forward to the imminent launch of emerging insulin analogues
and the biosimilar version of Lantus, Eli Lilly's Abasria.